Brand Name | Status | Last Update |
---|---|---|
tecentriq | Biologic Licensing Application | 2023-05-19 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
non-small-cell lung carcinoma | — | D002289 | — |
urinary bladder neoplasms | — | D001749 | C67 |
Expiration | Code | ||
---|---|---|---|
atezolizumab, Tecentriq, Genentech, Inc. | |||
2029-12-09 | Orphan excl. |
Code | Description |
---|---|
J9022 | Injection, atezolizumab, 10 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Non-small-cell lung carcinoma | D002289 | — | — | 100 | 143 | 52 | 2 | 31 | 276 |
Hepatocellular carcinoma | D006528 | — | C22.0 | 24 | 54 | 8 | 2 | 24 | 98 |
Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 27 | 36 | 11 | 2 | 19 | 83 |
Lung neoplasms | D008175 | HP_0100526 | C34.90 | 23 | 35 | 7 | 2 | 5 | 56 |
Interstitial lung diseases | D017563 | HP_0006530 | J84.89 | — | — | — | 1 | 1 | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 145 | 101 | 8 | — | 15 | 207 |
Melanoma | D008545 | — | — | 49 | 48 | 5 | — | 14 | 93 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 45 | 51 | 7 | — | 2 | 86 |
Triple negative breast neoplasms | D064726 | — | — | 33 | 33 | 11 | — | 2 | 62 |
Colorectal neoplasms | D015179 | — | — | 28 | 31 | 7 | — | — | 54 |
Renal cell carcinoma | D002292 | EFO_0000376 | — | 27 | 24 | 5 | — | 4 | 50 |
Urologic neoplasms | D014571 | — | C64-C68 | 22 | 24 | 4 | — | 6 | 48 |
Squamous cell carcinoma of head and neck | D000077195 | — | — | 26 | 25 | 4 | — | 3 | 44 |
Small cell lung carcinoma | D055752 | — | — | 16 | 22 | 6 | — | 5 | 43 |
Urinary bladder neoplasms | D001749 | — | C67 | 16 | 29 | 7 | — | — | 43 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Sarcoma | D012509 | — | — | 13 | 14 | — | — | 1 | 21 |
Squamous cell neoplasms | D018307 | — | — | 7 | 11 | — | — | 1 | 16 |
Lymphoma | D008223 | — | C85.9 | 12 | 8 | — | — | — | 15 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | 14 | 7 | — | — | — | 15 |
Glioblastoma | D005909 | EFO_0000515 | — | 8 | 9 | — | — | — | 11 |
Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | 3 | 8 | — | — | — | 9 |
Biliary tract neoplasms | D001661 | — | C24.9 | 3 | 8 | — | — | — | 8 |
Rectal neoplasms | D012004 | — | — | 3 | 7 | — | — | 1 | 8 |
Myeloid leukemia acute | D015470 | — | C92.0 | 8 | 4 | — | — | — | 8 |
Hodgkin disease | D006689 | — | C81 | 3 | 3 | — | — | — | 6 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Sezary syndrome | D012751 | — | C84.1 | 1 | — | — | — | — | 1 |
Large-cell lymphoma anaplastic | D017728 | — | C84.6 | 1 | — | — | — | — | 1 |
Leukemia | D007938 | — | C95 | 1 | — | — | — | — | 1 |
Hematologic diseases | D006402 | EFO_0005803 | D75.9 | 1 | — | — | — | — | 1 |
Myeloid leukemia | D007951 | — | C92 | 1 | — | — | — | — | 1 |
Preleukemia | D011289 | — | — | 1 | — | — | — | — | 1 |
Bone marrow diseases | D001855 | — | — | 1 | — | — | — | — | 1 |
Primary myelofibrosis | D055728 | — | D47.4 | 1 | — | — | — | — | 1 |
Polycythemia | D011086 | EFO_0005804 | D75.1 | 1 | — | — | — | — | 1 |
Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | — | — | 2 | 2 |
Myocarditis | D009205 | — | I51.4 | — | — | — | — | 2 | 2 |
Microbiota | D064307 | — | — | — | — | — | — | 2 | 2 |
Metagenome | D054892 | — | — | — | — | — | — | 2 | 2 |
Autoimmune diseases | D001327 | HP_0002960 | M30-M36 | — | — | — | — | 2 | 2 |
Venous thrombosis | D020246 | HP_0004936 | I82.40 | — | — | — | — | 1 | 1 |
Budd-chiari syndrome | D006502 | EFO_1000966 | I82.0 | — | — | — | — | 1 | 1 |
Cardiovascular diseases | D002318 | HP_0001626 | — | — | — | — | — | 1 | 1 |
Cardiomyopathies | D009202 | EFO_0000318 | I42 | — | — | — | — | 1 | 1 |
Pericarditis | D010493 | EFO_0007427 | I30 | — | — | — | — | 1 | 1 |
Drug common name | Atezolizumab |
INN | atezolizumab |
Description | Atezolizumab, sold under the brand name Tecentriq, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), small cell lung cancer (SCLC), hepatocellular carcinoma, and alveolar soft part sarcoma. It is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1).
|
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | >5XXY:H|heavy chain of atezolizumab fab
EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAY
LQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN
SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTMDPGGSHHHHHHHH
>5XXY:L|light chain of atezolizumab fab
DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQP
EDFATYYCQQYLYHPATFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ
ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
PDB | 5X8L, 5XXY |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL3707227 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB11595 |
UNII ID | 52CMI0WC3Y (ChemIDplus, GSRS) |